Skip to main content

Board of directors


Kerstin Valinder Strinnholm

Executive Chairman

Born 1960. Active in the company since 2022. Kerstin holds a degree in Journalism från the University of Gothenburg, Sweden. Kerstin brings more than 30 years of international pharma experience. She has worked in leading positions at e.g. AstraZeneca and Nycomed/Takeda, with a primary focus on commercial and business strategic areas. Currently Kerstin acts as business advisor at transactions within the life science fied and is also non-executive member of the boards of Camurus AB and Immedica AB.

Shareholding: 24 166 shares. Independent in relation to the company and the owners.

Anders Lundmark

Born 1958. Member since 2022. Amders holds a Master of Science in Business Administration and Economics from the Uppsala University. Anders has 25 years of experience years as a CFO along with growth-related operational responsibilities. He has worked extensively under private equity regimes as well as in both listed and privately held companies. Amongst them, he has been the CFO of Phadia Group, Iggesund Paperboard, Trelleborg Industries and Observer/Cision. He is currently Board member of Nordic Biosite Holding AB, Antrad Medical AB, Tellacq Group AB and Secure Appox AB.

Shareholding: 204 406 shares. Independent in relation to the company and the owners.

Håkan Wallin

Born 1962. Member since 2023. Håkan has many years of both operative and financial experience from advisory positions as well as from board- and management positions in both listed and non-listed life science companies. Previous positions include responsible partner for the life science sector within corporate finance at ABG Sundal Collier, Head of Business Development at Medivir and Chairman of the Board of Directors in Palette Life Sciences (previously Pharmanest AB) and auditor at Arthur Andersen. Håkan has experience from several other sectors and is today CFO at NP3 Fastigheter AB (publ.). He is Board member of Cibola Holding AB and HWA Advisory & Capital AB.

Shareholding: 0 shares. Independent in relation to the company.


Nikolaj Sørensen

Born 1972. Board members since 2021. Nikolaj Sörensen has more than 20 years of experience from the life science and the pharmaceutical industry in Sweden and abroad. Nikolaj today serves as President and CEO of Orexo AB. Previous appointments includes senior management positions at Pfizer and as management consultant at the Boston Consulting Group (BCG). Nikolaj has a M.Sc. in International Business from Copenhagen Business School. Nikolaj is Board member and CEO of Biolipox AB and a Board member of Gesynta Pharma AB.

Shareholding: 20 902 shares. independent from the company and owners.


Current shareholding is not automatically updated for the moment. Insiders no longer have obligation to report there shareholding. According to the regulatory requirements, the data shall be updated once a year.